---
title: "Immuron Limited Reports 34% Global Sales Growth in Q1 FY26, Driven by Strong Performance in Australia and USA"
description: "Immuron Limited reported a 34% increase in global sales for Q1 FY26, reaching AUD$2.0 million. Sales in Australia surged by 52% to AUD$1.6 million, driven by enhanced brand awareness and marketing eff"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260873134.md"
published_at: "2025-10-13T10:00:19.000Z"
---

# Immuron Limited Reports 34% Global Sales Growth in Q1 FY26, Driven by Strong Performance in Australia and USA

> Immuron Limited reported a 34% increase in global sales for Q1 FY26, reaching AUD$2.0 million. Sales in Australia surged by 52% to AUD$1.6 million, driven by enhanced brand awareness and marketing efforts. The U.S. market also saw a 44% rise to AUD$0.4 million, thanks to improvements in the Travelan® Amazon store. However, Canadian sales fell by 92% to AUD$0.0 million due to seasonal factors, with expectations for recovery later in the year through promotions and campaigns.

Immuron Limited has reported unaudited Q1 FY26 sales results, highlighting significant global growth for its Travelan® product. Global Q1 sales reached AUD$2.0 million, up 34% on the prior comparative period (pcp). In Australia, sales climbed 52% to AUD$1.6 million, attributed to increased brand awareness, digital and social media marketing, and new store listings. The U.S. market saw Q1 sales rise 44% to AUD$0.4 million, driven by enhancements to the Travelan® Amazon store and expanded social media marketing efforts. Conversely, Canadian Q1 sales dropped 92% to AUD$0.0 million, reflecting the typical seasonal lull following a pipeline fill into over a thousand retail doors in the previous year. The company expects sales in Canada to pick up later in the year with increased consumer promotions and brand awareness campaigns. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544242-en) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [IMRN.US - Immuron](https://longbridge.com/en/quote/IMRN.US.md)
- [IMC.AU - Immuron Limited](https://longbridge.com/en/quote/IMC.AU.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immuron Shareholders Back Ratification of Prior Share Issues at February 2026 EGM | Immuron Limited's shareholders approved all resolutions at an extraordinary general meeting on February 12, 2026, includ | [Link](https://longbridge.com/en/news/275764572.md) |
| Australian Clinical Labs Announces FY2026 Interim Dividend Of 3.75 AU CPS | Australian Clinical Labs Ltd :FY2026 INTERIM DIVIDEND 3.75 AU CPSH1 NET INCOME AUD 5.6 MILLIONH1 REVENUE AUD 365.4 MILLI | [Link](https://longbridge.com/en/news/276013973.md) |
| I Couldn’t Stop Wasting Time On Social Media. This 1 Easy Trick Helped Me Win Back My Attention. | The article discusses the author's experience with the Brick device, which helps users manage their social media usage.  | [Link](https://longbridge.com/en/news/275754373.md) |
| Australian Clinical Labs Group CEO Melinda Mcgrath Confirms Will Not Be Renewing Contract | Australian Clinical Labs Ltd :GROUP CEO MELINDA MCGRATH CONFIRMED WILL NOT BE RENEWING CONTRACT FOLLOWING CONCLUSION ON  | [Link](https://longbridge.com/en/news/276015451.md) |
| SocialPost.ai Launches AI That Turns Any Business Website Into On-Brand Social Media Content Automatically | SocialPost.ai has launched a new AI capability that automatically generates on-brand social media content by analyzing a | [Link](https://longbridge.com/en/news/275619165.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
